NCT01237951 2020-05-05
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)